UCB SA said that a Phase 2b study of its candidate antibody for rheumatoid arthritis, olokizumab, met its primary endpoint. But there was no improvement in efficacy when the drug was compared with tocilizumab (Actemra). ---Subscribe to MedNous to access this article--- Company News Clinical Research
